Recursive Superintelligence raises $650M to build self-improving AI models

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched ...

What happens when AI starts building itself?

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...
Fierce Biotech

After a decade of hype, Najat Khan is bringing Recursion back down to earth

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
C&EN

Recursion to buy AI rival Exscientia

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...

Recursion Pharmaceuticals (RXRX): Best AI Stocks Under $50 to Buy Right Now

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion ...
Seeking Alpha

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...

OpenAI Boasts Recursive AI: 3 Examples

OpenAI advances recursive AI; new startup pursues self-improving systems amid leaked experimental model names.

Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast

Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets simultaneously and helped cut clinical trial enrollment times by up to half, ...